Dr. Reddy's Laboratories Limited – NYSE:RDY
Dr. Reddy's Laboratories Limited stock price today
$14.4
-1.45
-9.21%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Dr. Reddy's Laboratories Limited stock price monthly change
-80.07%
month
Dr. Reddy's Laboratories Limited stock price quarterly change
-80.07%
quarter
Dr. Reddy's Laboratories Limited stock price yearly change
-76.73%
year
Dr. Reddy's Laboratories Limited key metrics
Market Cap | 12.82B |
Enterprise value | 1.16T |
P/E | 4.22 |
EV/Sales | 3.88 |
EV/EBITDA | 13.58 |
Price/Sales | 3.76 |
Price/Book | 0.73 |
PEG ratio | N/A |
EPS | 184.13 |
Revenue | 241.36B |
EBITDA | 66.5B |
Income | 30.60B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 17.79% |
Oper. margin | 22.52% |
Gross margin | 59.29% |
EBIT margin | 22.52% |
EBITDA margin | 27.55% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDr. Reddy's Laboratories Limited stock price history
Dr. Reddy's Laboratories Limited stock forecast
Dr. Reddy's Laboratories Limited financial statements
| Dec 2021 | 53.19B | 7.06B | 13.28% |
|---|---|---|---|
| Mar 2022 | 54.36B | 875M | 1.61% |
| Mar 2023 | 62.96B | 9.59B | 15.23% |
| Mar 2024 | 70.83B | 13.07B | 18.45% |
| Mar 2024 | 70.83B | 13.07B | 18.45% |
|---|---|---|---|
| Sep 2025 | 84.48B | 14.26B | 16.88% |
| Dec 2025 | 87.00B | 12.30B | 14.14% |
| Mar 2026 | 89.59B | 12.58B | 14.04% |
Analysts Price target
Financials & Ratios estimates
| 2024-07-27 | 0.22 | 0.2 |
|---|---|---|
| 2024-11-05 | 0.04434 | 0.04 |
3.02%
Yield TTM
| Payout ratio | 12.49% |
|---|
| 2020 | 3.89% |
|---|---|
| 2021 | 2.78% |
| 2022 | 2.95% |
| 2023 | 3.21% |
| 2024 | 3.24% |
| Sep 2022 | 290974000000 | 84.74B | 29.13% |
|---|---|---|---|
| Dec 2022 | 309300000000 | 52.04B | 16.83% |
| Mar 2023 | 322851000000 | 89.99B | 27.87% |
| Mar 2024 | 387518000000 | 106.96B | 27.6% |
| Dec 2021 | 17.33B | -2.76B | -2.56B |
|---|---|---|---|
| Mar 2022 | 9.11B | -21.98B | 5.09B |
| Mar 2023 | 19.67B | -15.77B | -4.29B |
| Mar 2024 | 11.52B | -11.35B | -533M |
Dr. Reddy's Laboratories Limited alternative data
| Aug 2023 | 25,863 |
|---|---|
| Sep 2023 | 25,863 |
| Oct 2023 | 25,863 |
| Nov 2023 | 25,863 |
| Dec 2023 | 25,863 |
| Jan 2024 | 25,863 |
| Feb 2024 | 25,863 |
| Mar 2024 | 25,863 |
| Apr 2024 | 25,863 |
| May 2024 | 25,863 |
| Jun 2024 | 25,863 |
| Jul 2024 | 27,048 |
Dr. Reddy's Laboratories Limited other data
8.65%
-0.75%
of RDY is owned by hedge funds
142
-5
14.39M
-1.24M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 26 Jun 2020 Issue date: 11 Aug 2022 |
Application METHOD FOR IDENTIFICATION AND ABSOLUTE QUANTIFICATION OF PRODUCT-RELATED IMPURITIES IN A PROTEIN USING HIGH-RESOLUTION MASS SPECTROMETRY Filling date: 3 Jun 2020 Issue date: 4 Aug 2022 |
Application Filling date: 22 May 2020 Issue date: 4 Aug 2022 |
Application Filling date: 15 May 2020 Issue date: 14 Jul 2022 |
Grant Filling date: 10 Jan 2017 Issue date: 12 Jul 2022 |
Application Filling date: 24 Mar 2020 Issue date: 2 Jun 2022 |
Application Filling date: 26 Feb 2020 Issue date: 12 May 2022 |
Grant Filling date: 9 Apr 2018 Issue date: 5 Apr 2022 |
Application Filling date: 10 Apr 2019 Issue date: 30 Dec 2021 |
Grant Filling date: 10 Aug 2018 Issue date: 9 Nov 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2024 7 May 2024 | Q4 2024 Earnings Call Transcript |
| Q3 2024 30 Jan 2024 | Q3 2024 Earnings Call Transcript |
| Q2 2024 27 Oct 2023 | Q2 2024 Earnings Call Transcript |
| Q1 2024 26 Jul 2023 | Q1 2024 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Gunupati Venkateswara Prasad B.E. (1960) Co-Chairman, MD & Member of Management Council | $2,100,000 |
Mr. Kallam Satish Reddy (1967) Chairman & Member of the Management Council | $1,410,000 |
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
From Euphoria To Reality: Viatris' Tale Of Market Whirlwind
Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook
The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Dr. Reddy's: Growth Supported By New Labels, Profitability
-
What's the price of Dr. Reddy's Laboratories Limited stock today?
One share of Dr. Reddy's Laboratories Limited stock can currently be purchased for approximately $14.4.
-
When is Dr. Reddy's Laboratories Limited's next earnings date?
Unfortunately, Dr. Reddy's Laboratories Limited's (RDY) next earnings date is currently unknown.
-
Does Dr. Reddy's Laboratories Limited pay dividends?
Yes, Dr. Reddy's Laboratories Limited pays dividends and its trailing 12-month yield is 3.02% with 12% payout ratio. The last Dr. Reddy's Laboratories Limited stock dividend of $0.29 was paid on 6 Sep 2025.
-
How much money does Dr. Reddy's Laboratories Limited make?
Dr. Reddy's Laboratories Limited has a market capitalization of 12.82B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 13.54% to 279.16B US dollars. Dr. Reddy's Laboratories Limited earned 55.68B US dollars in net income (profit) last year or $0.04 on an earnings per share basis.
-
What is Dr. Reddy's Laboratories Limited's stock symbol?
Dr. Reddy's Laboratories Limited is traded on the NYSE under the ticker symbol "RDY".
-
What is Dr. Reddy's Laboratories Limited's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Dr. Reddy's Laboratories Limited?
Shares of Dr. Reddy's Laboratories Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Dr. Reddy's Laboratories Limited's key executives?
Dr. Reddy's Laboratories Limited's management team includes the following people:
- Mr. Gunupati Venkateswara Prasad B.E. Co-Chairman, MD & Member of Management Council(age: 65, pay: $2,100,000)
- Mr. Kallam Satish Reddy Chairman & Member of the Management Council(age: 58, pay: $1,410,000)
-
How many employees does Dr. Reddy's Laboratories Limited have?
As Jul 2024, Dr. Reddy's Laboratories Limited employs 27,048 workers, which is 5% more then previous month and 5% more then previous quarter.
-
When Dr. Reddy's Laboratories Limited went public?
Dr. Reddy's Laboratories Limited is publicly traded company for more then 24 years since IPO on 11 Apr 2001.
-
What is Dr. Reddy's Laboratories Limited's official website?
The official website for Dr. Reddy's Laboratories Limited is drreddys.com.
-
How can i contact Dr. Reddy's Laboratories Limited?
Dr. Reddy's Laboratories Limited can be reached via phone at +91 40 4900 2900.
Dr. Reddy's Laboratories Limited company profile:
Dr. Reddy's Laboratories Limited
drreddys.comExchange:
NYSE
Full time employees:
27,048
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
8-2-337, Road No. 3
Hyderabad, 500034
Hyderabad, 500034
CIK: 0001135951
ISIN: US2561352038
CUSIP: 256135203
